Home › Compare › IIIIW vs ABBV

IIIIW vs ABBV: Dividend Comparison 2026

IIIIW yields 36363.64% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IIIIW wins by $2.004574200915329e+22M in total portfolio value
10 years
IIIIW
IIIIW
● Live price
36363.64%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.004574200915329e+22M
Annual income
$19,937,884,707,502,715,000,000,000,000.00
Full IIIIW calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — IIIIW vs ABBV

📍 IIIIW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIIIIWABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IIIIW + ABBV cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
IIIIW pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IIIIW
Annual income on $10K today (after 15% tax)
$3,090,909.09/yr
After 10yr DRIP, annual income (after tax)
$16,947,202,001,377,307,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, IIIIW beats the other by $16,947,202,001,377,307,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IIIIW + ABBV for your $10,000?

IIIIW: 50%ABBV: 50%
100% ABBV50/50100% IIIIW
Portfolio after 10yr
$1.0022871004576645e+22M
Annual income
$9,968,942,353,751,357,000,000,000,000.00/yr
Blended yield
99.46%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

IIIIW
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IIIIW buys
0
ABBV buys
0
No recent congressional trades found for IIIIW or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIIIIWABBV
Forward yield36363.64% ✓3.06%
Annual dividend / share$2.00$6.65 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6% ✓
Portfolio after 10y$2.004574200915329e+22M$102.3K ✓
Annual income after 10y$19,937,884,707,502,715,000,000,000,000.00 ✓$24,771.77
Total dividends collected$2.003865260522492e+22M$61.0K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: IIIIW vs ABBV ($10,000, DRIP)

YearIIIIW PortfolioIIIIW Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$3,647,064$3,636,363.64$11,550$430.00+$3.64M → IIIIW
2$1,243,346,245$1,239,443,886.61$13,472$627.96+$1243.33M → IIIIW
3$396,234,657,856$394,904,277,374.15$15,906$926.08+$396234.64M → IIIIW
4$118,040,520,159,692$117,616,549,075,786.05$19,071$1,382.55+$118040520.14M → IIIIW
5$32,872,684,322,908,456$32,746,380,966,337,588.00$23,302$2,095.81+$32872684322.89M → IIIIW
6$8,557,999,083,048,487,000$8,522,825,310,822,975,000.00$29,150$3,237.93+$8557999083048.46M → IIIIW
7$2,082,813,837,352,754,200,000$2,073,656,778,333,892,400,000.00$37,536$5,121.41+$2082813837352754.25M → IIIIW
8$473,891,076,116,906,500,000,000$471,662,465,310,939,100,000,000.00$50,079$8,338.38+$473891076116906496.00M → IIIIW
9$100,801,216,495,868,050,000,000,000$100,294,153,044,422,990,000,000,000.00$69,753$14,065.80+$100801216495868051456.00M → IIIIW
10$20,045,742,009,153,290,000,000,000,000$19,937,884,707,502,715,000,000,000,000.00$102,337$24,771.77+$2.004574200915329e+22M → IIIIW

IIIIW vs ABBV: Complete Analysis 2026

IIIIW — Stock

IIIIW is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in IIIIW shares.

Full IIIIW Calculator →

ABBV — Healthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this IIIIW vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IIIIW vs SCHDIIIIW vs JEPIIIIIW vs OIIIIW vs KOIIIIW vs MAINIIIIW vs JNJIIIIW vs MRKIIIIW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.